Last updated: February 12, 2026
What is the current market status for NDC 52817-0271?
The drug associated with NDC 52817-0271 is Difelikefalin (Brand: Korsuva), indicated for the treatment of pruritus in adults with chronic kidney disease (CKD) on dialysis. It gained FDA approval on August 21, 2021 (PDUFA date), and has since secured a significant market share in the niche therapeutic area.
Initial launch in late 2021 faced limited competition due to the absence of approved treatments specifically targeting CKD-associated pruritus. Key competitors include off-label antihistamines and topical therapies, but none have demonstrated consistent efficacy in this indication.
Market uptake has been steady, driven by:
- Clear unmet need for pruritus management in dialysis patients.
- Positive clinical trial data indicating significant symptom relief.
- Favorable safety profile, with minimal adverse events reported.
How has pricing evolved since approval?
Pricing was set at approximately $1,000 per dose (administration via subcutaneous injection), with a typical dose administered once weekly for CKD-associated pruritus. The annual treatment cost estimates around $52,000–$60,000 per patient, considering ongoing weekly administration.
Initial market entry focused on the dialysis centers, with coverage negotiated through Medicare and private insurers, setting the stage for reimbursement. Early discounts and contract negotiations targeted key dialysis providers.
What are the outlook and projections for current and future prices?
Short-term projections (2023-2024)
- The average wholesale price (AWP) is expected to stabilize around $1,000 per dose.
- Reimbursement levels are likely to range between $800–$1,000 per dose after negotiations.
- Adoption is projected to continue gradual growth, reaching approximately 20,000–30,000 patients globally by the end of 2024, mostly within the U.S. dialysis population.
Long-term projections (2025-2030)
- Competition could emerge from other emerging therapies, possibly reducing prices by 10-20%.
- Broader use in non-dialysis CKD patients with pruritus might expand the market, which could support sustained or increased pricing.
- Price pressure from payers may push manufacturer discounts or value-based agreements, potentially lowering effective prices.
Competitive landscape and impact on price
- Currently, no approved alternatives directly match Difelikefalin's efficacy, allowing stability in pricing.
- The potential entry of biosimilars or alternative therapies might initiate downward pricing pressure in 2026 and beyond.
- Market expansion into other pruritus indications could support maintaining or increasing prices if regulatory approvals are obtained.
Key factors influencing future pricing
- Reimbursement policies, notably Medicare coverage expansion.
- Clinical guideline endorsements for diffuse pruritus management.
- Entry of new competitors with superior efficacy or broader indications.
- Manufacturer strategies regarding discounts, patient assistance, and value-based contracts.
Summary table: Price projections (annual per patient)
| Year |
Price Range (per dose) |
Approximate Annual Cost |
Comments |
| 2023 |
$800–$1,000 |
$41,600–$52,000 |
Initial stabilization; insurance negotiations ongoing |
| 2024 |
$800–$1,000 |
$41,600–$52,000 |
Growth in patient base; competitive pressures may influence pricing |
| 2025 |
$720–$900 |
$37,440–$46,800 |
Potential market entry of competitors; volume growth could offset price drops |
| 2030 |
$600–$800 |
$31,200–$41,600 |
Possible biosimilar competition; broader indication expansion |
Final considerations
The pricing trajectory hinges on market penetration, payer negotiations, and competitive dynamics. Overall, Difelikefalin maintains premium positioning due to its approved indication and benefit profile, with moderate downward pressure expected through 2030.
Key Takeaways
- NDC 52817-0271 (Difelikefalin) launched in 2021 targeting CKD-associated pruritus.
- Initial pricing at approximately $1,000 per dose; annual costs around $52,000.
- Market projections suggest stable prices through 2024, with potential declines from competitive entry and biosimilar development thereafter.
- Drug adoption remains driven by limited current alternatives, insurance coverage, and demand in dialysis populations.
- Future price adjustments will depend on payer negotiations, broader indications, and competitive landscape shifts.
FAQs
-
What factors could lead to a significant price decrease for Difelikefalin?
Entry of biosimilars or alternative therapies, changes in reimbursement policies, or expanded indications reducing reliance on the drug could lower prices.
-
How does the drug's pricing compare to similar therapeutics?
As a niche drug with no direct competitors, its price exceeds typical anti-pruritic agents, which often cost less than $200 per month. Its premium reflects its specialized indication and efficacy.
-
Will prices increase with broader use outside dialysis settings?
Expansion into non-dialysis CKD or other pruritus indications could support higher volume and potentially justify incremental price adjustments, but payers may counter with discounts.
-
What are reimbursement prospects for clinics using Difelikefalin?
Coverage via Medicare Part B and private insurers is favorable; negotiated reimbursement levels typically hover around 80-100% of the wholesale price, supporting access.
-
When are biosimilars or alternative drugs likely to enter the market?
No biosimilars currently exist; potential entrants are expected beyond 2025, contingent on regulatory pathways and development timelines.
Sources:
- FDA approval documents for Difelikefalin (August 2021).
- Market reports on CKD-associated pruritus therapeutics (Q4 2022).
- Pricing data from Medicare and private insurer reimbursement policies.
- Current literature and clinical guidelines on pruritus in CKD.
